LOS ANGELES / Jul 15, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim safety analysis of the trial demonstrated that ENV-105, a... Read More

LOS ANGELES / Jun 03, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill. In the presentation titled, “Effect... Read More

Los Angeles, California--(Newsfile Corp. - May 6, 2025) - Kairos Pharma, Ltd. (NYSE American: KAPA) today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City. John Yu, MD, CEO and Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. (ET). To register for one-on-one meetings with management at The Plaza... Read More

LOS ANGELES / Apr 28, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill. The poster is titled, “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and... Read More

LOS ANGELES / Apr 24, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.: To our valued stockholders, As we reflect on the Company’s progress before and after our initial public offering and listing on the NYSE American stock exchange, I am excited about what the future holds. We currently have two... Read More

LOS ANGELES / Apr 17, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to single-agent osimertinib in a Phase 1 trial. Based on recent breakthroughs in understanding non-small cell lung cancer mechanism of resistance to first line osimertinib treatment, the... Read More

Company expects safety data readout in 2025 as Randomized Arm continues enrollment at key medical centers LOS ANGELES / Mar 31, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company (the “Company’”), announces the completion of the safety lead-in of its Phase 2 clinical trial of ENV105 for the treatment of metastatic, castration-resistant prostate cancer. The trial,... Read More

LOS ANGELES / Mar 27, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, highlights activity at recent scientific conferences and announces participation in future events. Highlights include: March 12, 2025 – Presented at the Society for Immunotherapy of Cancer Spring Scientific Meeting titled, “Novel GITR Agonist KROS 101: A Dual Approach to Boost T Cell Immunity... Read More

LOS ANGELES / Mar 20, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a peer-reviewed publication highlighting a potentially significant breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer (NSCLC) patients. Recent findings published in Drug Resistance Updates highlight the critical role of CD105 (endoglin)... Read More

LOS ANGELES / Feb 26, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced that the company presented preclinical data on its investigational compounds KROS 101 and KROS 401 during the American Association for Cancer Research Immuno-Oncology (AACR IO) conference held in Los Angeles from February 23-26, 2025. The data highlighted positive preclinical outcomes... Read More

LOS ANGELES / Feb 18, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with Cedars-Sinai Medical Center, Cedars-Sinai has received $600,000 in funding from the Department of Defense Lung Cancer Research Program to advance the development of ENV205, a groundbreaking new drug to treat chemotherapy drug resistance and... Read More

ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments. LOS ANGELES / Feb 11, 2025 / Business Wire / Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of Huntsman Cancer Institute in Salt Lake City, Utah for the... Read More

LOS ANGELES / Feb 06, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company presented a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, highlighting preclinical data on its glutocorticoid-induced tumor necrosis factor receptor (GITR) agonist, KROS101. In the talk,... Read More

LOS ANGELES / Jan 28, 2025 / Business Wire / Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, being held February 1-5, 2025 in Maui, Hawaii. The talk, titled, “KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor... Read More

LOS ANGELES / Jan 21, 2025 / Business Wire / Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, provides an overview of key 2024 milestones and outlook into 2025 in a Letter to Shareholders: Dear Kairos Pharma Shareholders, The management team and Board of Directors of Kairos Pharma Ltd. are pleased to... Read More

LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma , (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025 , the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. Kairos Pharma's management team will deliver a corporate... Read More

ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments. LOS ANGELES / Dec 03, 2024 / Business Wire / Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the... Read More